Literature DB >> 15676111

Inflammatory neuropathies.

Hannah R Briemberg1, Anthony A Amato.   

Abstract

We discuss two of the most common of the acquired inflammatory neuropathies: Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy, as well as their variants. We review their clinical presentation, electrophysiologic findings, and management, highlighting knowledge gained from the recent literature. Unfortunately, although treatments exist for both Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy, none are completely curative and all have significant potential side effects and/or expense. Better understanding of the underlying pathophysiology of these diseases is needed in order to develop more targeted therapies.

Entities:  

Mesh:

Year:  2005        PMID: 15676111     DOI: 10.1007/s11910-005-0026-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  37 in total

1.  Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation.

Authors:  J Pritchard; R Mukherjee; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

2.  Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy.

Authors:  Alexander J Radziwill; Andreas J Steck; Susanne Renaud; Peter Fuhr
Journal:  J Neurol       Date:  2003-08       Impact factor: 4.849

3.  Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies.

Authors:  E Nobile-Orazio; N Meucci; L Baldini; A Di Troia; G Scarlato
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

4.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

5.  Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy.

Authors:  K C Gorson; A H Ropper; D H Weinberg; R Weinstein
Journal:  Muscle Nerve       Date:  2001-06       Impact factor: 3.217

6.  A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy.

Authors:  M C Dalakas; R H Quarles; R G Farrer; J Dambrosia; S Soueidan; D P Stein; E Cupler; E A Sekul; C Otero
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

7.  Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

Authors:  A F Hahn; C F Bolton; N Pillay; C Chalk; T Benstead; V Bril; K Shumak; M K Vandervoort; T E Feasby
Journal:  Brain       Date:  1996-08       Impact factor: 13.501

8.  Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R A C Hughes; E F M Wijdicks; R Barohn; E Benson; D R Cornblath; A F Hahn; J M Meythaler; R G Miller; J T Sladky; J C Stevens
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

Review 9.  Immune mechanisms in chronic inflammatory demyelinating neuropathy.

Authors:  Bernd C Kieseier; Marinos C Dalakas; Hans-Peter Hartung
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

10.  The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

Authors:  T Lasky; G J Terracciano; L Magder; C L Koski; M Ballesteros; D Nash; S Clark; P Haber; P D Stolley; L B Schonberger; R T Chen
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

View more
  3 in total

1.  A case of acute motor and sensory axonal neuropathy following hepatitis a infection.

Authors:  Yoon-Sik Jo; Sang-Don Han; Jin-Yong Choi; Ick Hee Kim; Yong-Duk Kim; Sang-Jun Na
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

Review 2.  Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.

Authors:  Richard J Bright; Jenny Wilkinson; Brendon J Coventry
Journal:  BMC Neurol       Date:  2014-02-07       Impact factor: 2.474

3.  Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis.

Authors:  Cecilia Smith Simonsen; Gunnar Hansen; Fredrik Piehl; Astrid Edland
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.